MarkRobertKeatonMDFACP

PubMed

• 3 citations
  Anti-HER-2 therapy following severe trastuzumab-induced cardiac toxicity
  Mark Robert Keaton, Nita J. Maihle, Shou Ching Tang> ;Genes & Diseases. 2017 Sep 1
• 17 citations
  TITAN: phase III study of doxorubicin/cyclophosphamide followed by ixabepilone or paclitaxel in early-stage triple-negative breast cancer
  Denise A. Yardley, Edward Arrowsmith, Brooke R. Daniel, Janice F. Eakle, Adam Brufsky, David Drosick, Fred J. Kudrik, Linda D. Bosserman, Mark Keaton, Sharon A. Goble,...> ;Breast Cancer Research and Treatment. 2017 May 15
• Highlights of the 2015 San Antonio Breast Cancer Symposium
  Mark Robert Keaton, Debu Tripathy, Joyce O'Shaughnessy, Shou Ching Tang> ;Genes & Diseases. 2016 Jun 1
• 10 citations
  Phase II multicenter study of docetaxel and bevacizumab with or without trastuzumab as first-line treatment for patients with metastatic breast cancer.
  Lee S. Schwartzberg, Suprith Badarinath, Mark Keaton, Barrett H. Childs> ;Clinical Breast Cancer. 2014 Jun 1
• Improved time to treatment failure with an intermittent oxaliplatin strategy: results of CONcePT.
  Hochster HS Grothey A Hart L Rowland K Ansari R Alberts S Chowhan N Ramanathan RK Keaton M Hainsworth JD Childs BH> ;Ann Oncol. 2014 Jun
• 51 citations
  Sorafenib or Placebo with Either Gemcitabine or Capecitabine in Patients with HER-2–Negative Advanced Breast Cancer That Progressed during or after Bevacizumab
  Lee S. Schwartzberg, Kurt W. Tauer, Robert Hermann, Grace Makari-Judson, Claudine Isaacs, J. Thaddeus Beck, Virginia G. Kaklamani, Edward J. Stepanski, Hope S. Rugo, W...> ;Clinical Cancer Research. 2013 May 15
• 42 citations
  A phase II randomized study of cetuximab and bevacizumab alone or in combination with gemcitabine as first-line therapy for metastatic pancreatic adenocarcinoma
  Andrew H. Ko, Hagop Youssoufian, Jayne Gurtler, Karel Dicke, Omar Kayaleh, Heinz-Josef Lenz, Mark Keaton, Terry Katz, Shaila Ballal, Eric K. Rowinsky> ;Investigational New Drugs. 2012 Aug 1
• 24 citations
  A randomized phase II study of paclitaxel and bevacizumab with and without gemcitabine as first-line treatment for metastatic breast cancer.
  Adam Brufsky, Karen Hoelzer, Thaddeus Beck, Robert C. Whorf, Mark Keaton, Padma Nadella, Elisa Krill-Jackson, Joan Kroener, Edward Middleman, Michael Frontiera, Devcha...> ;Clinical Breast Cancer. 2011 Aug 1
• 51 citations
  A phase II study of weekly nanoparticle albumin-bound paclitaxel with or without trastuzumab in metastatic breast cancer.
  Barry Mirtsching, Thomas Cosgriff, Graydon Harker, Mark Keaton, Tarek Chidiac, Myo Min> ;Clinical Breast Cancer. 2011 Apr 1
• 10 citations
  A phase II trial of pemetrexed and gemcitabine as first line therapy for poor performance status and/or elderly patients with stage IIIB/IV non-small cell lung cancer.
  L. Johnetta Blakely, Lee S. Schwartzberg, Mark Keaton, Fred Schnell, David H. Henry, Amanda L. Epperson, Mark S. Walker> ;Lung Cancer. 2009 Oct 1
• Preliminary results of a randomized phase II study of paclitaxel and bevacizumab ± gemcitabine as first-line treatment for metastatic breast cancer.
  Hoelzer KL, Brufsky A, Hainsworth J, Beck JT, Whorf R, Keaton M, Kroener J, Krill-Jackson E, Hu S, Bromund J> ;J. Clin. Oncol.. 2009-05-20
• Single-agent nab-paclitaxel given weekly (3/4) as first-line therapy for metastatic breast cancer (an International Oncology Network study, #I-04-012).
  Mirtsching B, Cosgriff T, Harker G, Keaton M, Chidiac T, Min M> ;J. Clin. Oncol.. 2008-05-20
• A phase II study of paclitaxel and bevacizumab ± gemcitabine as first-line treatment for metastatic breast cancer (MBC): Interim safety results.
  Brufsky AM, Hoelzer KL, Keaton MR, Beck JT, Krill-Jackson E, Wang Y, Hu S, Vaughn LG, Shonukan OO> ;J. Clin. Oncol.. 2008-05-20
• Phase II trial of pemetrexed (P) and gemcitabine (G) as first-line chemotherapy for elderly and/or poor performance status patients with stage IIIB/IV non-small cell l...
  Blakely J, Schnell F, Kaywin P, Keaton M, Fortner B, Epperson A, Schwartzberg LS> ;J. Clin. Oncol.. 2006-06-20
• Phase II study of carbetimer in non-small cell lung cancer.
  Keaton M, Brown T, Craig J, Fries G, Harmon G, Zaloznik A, Orczyk G, Von Hoff D> ;Invest New Drugs. 1990-11-01
• Acute renal failure in an alcoholic during therapeutic acetaminophen ingestion.
  Keaton, M. R.> ;South Med J. 1988 Sep
• Join now to see all

Journal Articles

• A Phase II study of carbetimer in non-small cell lung cancer  
  Keaton M, Brown T,Craig J et al, Invest New Drugs, 11/8/1990